Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,708.60
Bid: 1,708.40
Ask: 1,708.80
Change: 3.40 (0.20%)
Spread: 0.40 (0.023%)
Open: 1,701.60
High: 1,713.00
Low: 1,699.40
Prev. Close: 1,705.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-In U.S., flu vaccine worked in just over half of those who got it

Thu, 21st Feb 2013 22:49

* Protection even lower among people 65 and older

* Officials say findings underscore need for better vaccines

By Julie Steenhuysen

CHICAGO, Feb 21 (Reuters) - A U.S. government analysis ofthis season's flu vaccine suggests it was effective in only 56percent of people who got the shot, and it largely failed toprotect the elderly against an especially deadly straincirculating during flu season.

The U.S. Centers for Disease Control and Prevention said thefindings underscore the need for more effective weapons in thefight against influenza, which kills between 3,000 and 50,000people in the United States each year depending on the severityof the flu season.

"We simply need a better vaccine against influenza, one thatworks better and lasts longer," CDC Director Dr. Thomas Friedensaid in a statement on Thursday.

Experts generally estimate the effectiveness of flu vaccinesto be between 50 percent and 70 percent, but this vaccineappears to have fallen on the low side of that range.

The vaccine did cut the risk of medical visits caused byeither influenza A or influenza B by 56 percent, according tothe study published in the CDC's Morbidity and Mortality WeeklyReport.

It was more effective against influenza B, protecting 67percent of those who were vaccinated. Against the influenza A(H3N2) strain, the vaccine protected only 47 percent.

The protective benefits of the vaccine against influenza Bwere consistent across age groups. That was not the case withthe influenza A (H3N2) component of the vaccine, which protected46 percent to 58 percent of people aged 6 months to 64 years,but only 9 percent of those 65 and older, a finding that wasstatistically insignificant.

The estimates are based on studies of 2,697 children andadults enrolled in the U.S. Influenza Vaccine EffectivenessNetwork between Dec. 3 and Jan. 19. The CDC said those estimatesmay change by the end of the flu season, when more people havebeen sampled.

Even so, the findings suggest that a large group of elderlypeople, who are consistently the most vulnerable to influenza, were unprotected during this year's flu season.

POOR IMMUNE RESPONSE TO VACCINES

One possible explanation may be that in older individuals,the immune system often produces a less robust immune responseto vaccines, or to any infection.

CDC experts suggested that poor immune response to theinfluenza A (H3N2) component of the vaccine may help explain whythe elderly were not protected, but said in the report thefindings "should not discourage future vaccination by personsaged 65 years (or older), who are at greater risk for moresevere cases and complications from influenza."

Dr. Joseph Bresee, a flu expert at the CDC, said overall thevaccine worked "OK," but it is not fully clear why people over65 responded poorly.

"Part of it is they are elderly and they respond lessvigorously to vaccines. But it appears that some of the people,at least, developed a less robust response to this particularantigen," he said, referring to the H3N2 component of the fluvaccine.

"Why that is, I don't think we know yet. We're looking at itclosely," he said.

Bresee said most of the elderly in the study tookconventional flu vaccine, and not the high-dose versiondeveloped by vaccine giant Sanofi to address issues ofpoor immune responses in the elderly.

"We'd love to be able to look at the question of whether itis actually more effective or not. We just don't have enough useyet," he said.

Sanofi said it shipped 6 million doses of the specialformulation for the elderly, but it did not have information onhow many of the doses were used, or whether any had been used bypatients in the study.

What is clear, Bresee said, is the need for the elderly whoget sick with flu symptoms to seek treatment with antiviralmedications, such as Roche Holding Ag's Tamiflu, whichcan reduce the severity of their illness.

CDC noted that vaccine effectiveness has been known to varybased on a number of factors including virus type, age, theparticular flu season and variations in an individual'simmunity.

"Although it's far from perfect, flu vaccination is by farthe best tool we have to protect from flu," Frieden said.

BETTER VACCINES

Frieden said the U.S. Department of Health and HumanServices as well as pharmaceutical companies are working toproduce better vaccines. Efforts include the use of geneticengineering to develop more potent and more modern flu vaccines,with the hope of ultimately developing a universal flu vaccinethat could protect against all strains of flu. Experts predictthat could be possible within eight to 10 years.

"It's going to be hard but it's well worth the effort,"Frieden said.

Already there are signs of change. In November, the Swissdrugmaker Novartis won U.S. Food and DrugAdministration approval for Flucelvax, a seasonal flu vaccinegrown in animal cell cultures instead of live chicken eggs, aspeedier and more reliable process that could help buildstockpiles in the event of a pandemic.

In December, GlaxoSmithKline won FDA approval for anew seasonal flu shot called Fluarix that protects against fourstrains of seasonal flu - known as a quadrivalent vaccine -instead of three strains, known as a trivalent vaccine. Theannouncement followed the approval last February ofAstraZeneca's four-strain flu nasal spray made by thecompany's MedImmune unit. Current vaccines tackled two A strainsand one B strain. The quadrivalent vaccines will add anadditional B strain.

Last month, the FDA approved the first gene-based fluvaccine developed by privately held Protein Sciences Corp, whichuses genetic engineering to grow portions of the virus in insectcells.

"What we're looking at is really incremental improvements,because if we could make the breakthrough improvements easily itwould have happened already," Dr. Leonard Friedland, vicepresident of clinical and medical affairs for vaccines in NorthAmerica at GlaxoSmithKline, said in an interview last month.

Glaxo's Fluarix is the first inactivated flu shot to includefour instead of three strains of flu.

"It was just licensed and will be available for nextseason," Friedland said, noting that Sanofi is also in theprocess of having their four-strain flu vaccine approved.

AstraZeneca's FluMist, a live, attenuated or weakened fluvaccine, will also have a four-strain version available for nextflu season.

Dr. Chris Ambrose, a vice president at AstraZeneca'sMedImmune unit, said the company plans to completely switch tothe four-strain version of Flumist.

Sanofi Spokeswoman Donna Cary said the company has producedflu vaccines for specific age groups, including its high dosevaccine for the elderly.

"The next step for the future is to get to the point wherewe don't need to develop a new vaccine every year," Cary said."The main thing we are all looking forward to is the universalvaccine."

More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.